Cargando…
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the observation that PD-1 and CTLA-4 are co-expressed by tumor-infiltrating lymphocytes, an inves...
Autores principales: | Berezhnoy, Alexey, Sumrow, Bradley J., Stahl, Kurt, Shah, Kalpana, Liu, Daorong, Li, Jonathan, Hao, Su-Shin, De Costa, Anushka, Kaul, Sanjeev, Bendell, Johanna, Cote, Gregory M., Luke, Jason J., Sanborn, Rachel E., Sharma, Manish R., Chen, Francine, Li, Hua, Diedrich, Gundo, Bonvini, Ezio, Moore, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762776/ https://www.ncbi.nlm.nih.gov/pubmed/33377134 http://dx.doi.org/10.1016/j.xcrm.2020.100163 |
Ejemplares similares
-
Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules
por: Pollara, Justin, et al.
Publicado: (2020) -
Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART(®) Molecules
por: Tuyishime, Marina, et al.
Publicado: (2021) -
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023) -
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
por: Root, Adam R., et al.
Publicado: (2016) -
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
por: Luke, Jason J., et al.
Publicado: (2023)